Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.41 USD
0.00 (-0.19%)
Updated Jun 12, 2024 03:57 PM ET
After-Market: $0.42 +0.01 (2.31%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Redhill Biopharma Ltd. [RDHL]
Reports for Purchase
Showing records 141 - 160 ( 228 total )
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Multiple Clinical and Commerical Milestones in 2017; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Pipeline Update - Crohn''s Catalyst Looms in 2Q17
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Protocol Updates Make MAP US a More Robust Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Updates on Clinical Progress and Commercial Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
2Q16 Recap - In-line; Focus on RHB-104 Crohn''s Interim Analysis
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Visibility on RHB-105; Pending 2H16 Catalysts for RHB-104 and Bekinda
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Late-Stage Programs and Pipeline Progression Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
New Phase 2 Study Investigates the Potential of Bekinda for IBS-D; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Encouraging Early-Stage Clinical Data Validates RHB-104 Potential; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Multiple Clinical Readouts Expected in 2016; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S